Loading page...
Loading page...
Kurma Partners SA · Multi-Country
Kurma Biofund III is an early-stage life sciences venture capital fund managed by Kurma Partners, based in Paris. The 2020-vintage fund of around EUR 160M backs European biotech companies, particularly in rare diseases, and has exited Amolyt Pharma to AstraZeneca and Emergence Therapeutics to Eli Lilly.
Choose your AI and follow the walkthrough. Your free EUACC account connects the two.
Illustrated walkthrough
https://www.euacc.ai/api/mcpWorks on every Claude plan, including Free (one custom connector). On Team and Enterprise, an Owner adds it.
On a phone, add it at claude.ai in your browser. It then shows up in the Claude app the next time you sign in.
Use EUACC to explore “Kurma biofund iii fpci” (https://www.euacc.ai/investors/kurma-biofund-iii-fpci). Help me assess investor fit and prepare questions using the available fund profiles. Cite the available sources and flag missing or outdated information.